Eikon Therapeutics, Inc. Common Stock (EIKN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Eikon Therapeutics, Inc. Common Stock in 2026. The next earnings report is expected on September 2, 2026.
Eikon Therapeutics missed consensus estimates in its latest earnings report, with EPS of $-1.63 falling short of the $-1.585 estimate and revenue of $0 meeting expectations. In the previous report EPS also missed expectations while revenue likewise met estimates.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.